Merck & Co., Inc. vs United States Oil ETF — how do they compare? Merck & Co., Inc. trades at $131.79 (market cap $321.77B), while United States Oil ETF trades at $126.63. The key difference: Merck & Co., Inc. pays a 2.61% dividend while United States Oil ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| MRK | USO | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | — |
52-Week High | $131.84 | $152.96 |
52-Week Low | $77.60 | $66.17 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
USO is trading at $126.49, up 0.45% with bullish technical momentum as moving averages signal strength. The stock faces mixed sentiment amid ongoing Middle East supply disruptions and OPEC demand forecast revisions. Recent headlines highlight volatility from Hormuz tensions and shifting oil market dynamics.
Outlook remains volatile with supply risks supporting prices but demand concerns creating headwinds. Key resistance at $128-$132 and support at $123-$119 will dictate near-term direction. Geopolitical developments and inventory data remain critical catalysts for oil-linked equities.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →